S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
Log in
NASDAQ:EGRX

Eagle Pharmaceuticals Stock Forecast, Price & News

$40.32
-0.08 (-0.20 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.90
Now: $40.32
$42.17
50-Day Range
$40.40
MA: $47.58
$50.73
52-Week Range
$33.80
Now: $40.32
$56.16
Volume133,795 shs
Average Volume120,517 shs
Market Capitalization$525.37 million
P/E Ratio115.20
Dividend YieldN/A
Beta0.74
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Eagle Pharmaceuticals logo

Headlines

Earnings Preview: Eagle Pharmaceuticals
March 1, 2021 |  finance.yahoo.com
FDA CRL
February 2, 2021 |  benzinga.com
Is EGRX A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
Eagle Pharmaceuticals up 8% on Q3 beat
November 2, 2020 |  seekingalpha.com
Eagle Pharmaceuticals Reports Third Quarter 2020 Results
November 2, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300
Employees108
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.89 million
Cash Flow$1.47 per share
Book Value$13.11 per share

Profitability

Net Income$14.31 million

Miscellaneous

Market Cap$525.37 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

248th out of 1,968 stocks

Pharmaceutical Preparations Industry

115th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$40.32
-0.08 (-0.20 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eagle Pharmaceuticals?

Wall Street analysts have given Eagle Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Eagle Pharmaceuticals
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Monday, March, 1st. The specialty pharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $2.38. Eagle Pharmaceuticals had a net margin of 2.65% and a trailing twelve-month return on equity of 8.50%.
View Eagle Pharmaceuticals' earnings history
.

How has Eagle Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EGRX shares have increased by 3.2% and is now trading at $40.32.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EGRX?

2 brokers have issued 1 year target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $59.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $52.50 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Mr. Scott L. Tarriff, Founder, Pres, CEO & Director (Age 61, Pay $2.33M)
  • Mr. David M. Pernock, Chief Operating Officer (Age 68, Pay $1.28M)
  • Mr. Brian Joseph Cahill, Chief Financial Officer
  • Mr. Michael W. Cordera, Exec. VP, Gen. Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor, Exec. VP, Chief Strategy Officer & Head of Corp. Devel. (Age 41)
  • Mr. Michael Moran, Exec. VP and Head of Sales, Bus. Devel. & Gov. Affairs
  • Dr. Judith Ng-Cashin, Exec. VP & Chief Medical Officer
  • Mr. John Kimmet, Exec. VP of Marketing Oncology & Acute Care
  • Dr. Valentin R. Curt M.D., Sr. VP of Clinical Drug Devel.
  • Dr. Gaozhong Zhu Ph.D., Sr. VP of Pharmaceutical Devel.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.90%), Janus Henderson Group PLC (13.00%), Park West Asset Management LLC (6.08%), Armistice Capital LLC (2.79%), Dimensional Fund Advisors LP (2.36%) and Brandes Investment Partners LP (2.03%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff.
View institutional ownership trends for Eagle Pharmaceuticals
.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Renaissance Technologies LLC, Aviva PLC, Los Angeles Capital Management LLC, ClariVest Asset Management LLC, Engineers Gate Manager LP, Northern Trust Corp, and Russell Investments Group Ltd..
View insider buying and selling activity for Eagle Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Park West Asset Management LLC, Brandes Investment Partners LP, SG Americas Securities LLC, Federated Hermes Inc., BlackRock Inc., Morgan Stanley, and JPMorgan Chase & Co..
View insider buying and selling activity for Eagle Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $40.32.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $525.37 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 108 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.